Erdosteine

• Description :

  Erdosteine inhibits lipopolysaccharide (LPS) -induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].

• Product Name Alternative :

  RV 144

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Bacterial; NF-κB

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; NF-κB

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Infection; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Erdosteine.html

• Purity :

  99.83

• Solubility :

  DMSO : 50 mg/mL (ultrasonic) |H2O : 6.67 mg/mL (ultrasonic)

• Smiles :

  O=C(O)CSCC(NC(CCS1)C1=O)=O

• Molecular Formula :

  C8H11NO4S2

• Molecular Weight :

  249.31

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39 (4) :1573-81.|[2]Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26 (7) :433-8.|[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  NF-κB

• CAS Number :

  [84611-23-4]